Salix Pharmaceuticals, Ltd. (SLXP) Thursday reported net income for the fourth-quarter of $17.6 million or $0.28 per share, compared to $33.6 million or $0.56 per share in the same period last year.
Adjusted earnings were $51 million or $0.81 per share. On average, 14 analysts polled by Thomson Reuters expected the company to earn $0.79 per share for the quarter. Analysts' estimates typically exclude special items.
Net product revenues were $198.17 million, up from $155.18 million in the year-ago quarter, while sixteen analysts expected revenues of $199.62 million.
In line with the full year 2013 guidance, for the first quarter of 2013 the company anticipates total company product revenue of about $200 million and adjusted net income to be approximately $40 million, or $0.63 per share.
Analysts currently expect first quarter earnings of $0.69 per share on revenues of $206.14 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.